Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VLX-1005

            Therapeutic Area: Hematology Product Name: VLX-1005

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hatteras Venture

            Deal Size: $16.6 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing June 16, 2021

            Details:

            The Series A financing, will support Veralox's efforts to advance the development program for its lead product candidate VLX-1005 for the treatment of heparin-induced thrombocytopenia (HIT).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OMS906

            Therapeutic Area: Hematology Product Name: OMS906

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 16, 2020

            Details:

            The presentation included data demonstrating that a single dose of OMS906 in an animal study demonstrated a decrease of mature CFD and an increase and accumulation in pro-CFD levels that remained detectable for more than three weeks.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EP-7041

            Therapeutic Area: Hematology Product Name: EP-7041

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 17, 2020

            Details:

            By preferentially inhibiting thrombosis but not normal hemostasis, EP-7041 holds the promise of preventing circuit and vascular thromboembolism with substantially less inhibition of the local hemostasis required for bleeding control in trauma or surgical procedures.